Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cohn

Showing results (421-430 of 612) with videos related to

Pageof 62
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1996
Loss of DCC expression in neuroblastoma is associated with disease disseminationM A Reale, M Reyes-Mugica, W E Pierceall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group studyRani E George, Wendy B London, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage diseaseM Omura-Minamisawa, M B Diccianni, R C Chang, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2001
Tolerance and pharmacokinetic interactions of rifabutin and azithromycinR Hafner, J Bethel, H C Standiford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyJulie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group studyWendy B London, Christopher N Frantz, Laura A Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCNS L Cohn, W B London, D Huang, et al.
Oncogene|January 23, 2004
MYCN-mediated regulation of the MRP1 promoter in human neuroblastomaChitra F Manohar, James A Bray, Helen R Salwen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2020
Community-acquired Pneumonia Guideline Recommendations-Impact of a Consensus-based Process versus Systematic ReviewsKevin C Wilson, Noah C Schoenberg, David L Cohn, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
Pageof 62

Showing results (421-430 of 612) with videos related to

Sort By:
Pageof 62
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1996
Loss of DCC expression in neuroblastoma is associated with disease disseminationM A Reale, M Reyes-Mugica, W E Pierceall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group studyRani E George, Wendy B London, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage diseaseM Omura-Minamisawa, M B Diccianni, R C Chang, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2001
Tolerance and pharmacokinetic interactions of rifabutin and azithromycinR Hafner, J Bethel, H C Standiford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyJulie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group studyWendy B London, Christopher N Frantz, Laura A Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCNS L Cohn, W B London, D Huang, et al.
Oncogene|January 23, 2004
MYCN-mediated regulation of the MRP1 promoter in human neuroblastomaChitra F Manohar, James A Bray, Helen R Salwen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2020
Community-acquired Pneumonia Guideline Recommendations-Impact of a Consensus-based Process versus Systematic ReviewsKevin C Wilson, Noah C Schoenberg, David L Cohn, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.
Pageof 62